Terlipressin for septic shock patients: a meta-analysis of randomized controlled study

Table 2 Further subgroup analysis and sensitivity analyses on primary outcome of mortality rate

	Groups	References	Patient number (TP/Ctrl)	Event (TP/Ctrl)	RR (95%CI)	I ²	P
Subgroup analyses
Type of control	NE	[2, 8,9,10, 13, 21,22,23]	425/413	200/202	0.95 (0.85,1.06)	0%	0.33
Type of control	DA	[14, 20]	46/44	27/28	0.92 (0.67,1.26)	0%	0.61
Published year	After 2010	[2, 5, 20,21,22,23]	377/384	169/182	0.95 (0.84,1.07)	8%	0.40
Published year	Before 2010	[9, 10, 13, 14]	94/73	58/48	0.92 (0.74,1.16)	0%	0.49
Study designed	Blinded	[8, 21]	275/283	109/114	0.73 (0.31,1.72)	79%	0.48
Study designed	Unblinded	[2, 9, 10, 13, 14, 20, 22, 23]	196/174	118/116	0.93 (0.83,1.05)	0%	0.24
TP dose	< 2 mg/d	[9, 10, 13, 22]	95/71	47/36	0.92 (0.69,1.22)	0%	0.55
	2–4 mg/d	[2, 8, 14, 20, 21]	334/344	148/158	0.96 (0.82,1.12)	0%	0.61
	> 4 mg/d	[23]	42/42	32/36	0.89 (0.72,1.10)	0%	0.27
Administration route	Bolus	[9, 13, 21]	64/47	36/31	0.81 (0.46,1.40)	51%	0.44
Administration route	Continuous infusion	[2, 8, 10, 14, 20, 22, 23]	407/410	191/199	0.96 (0.86,1.07)	0%	0.42
Sensitivity analyses
	28-day mortality	[2, 20, 22, 23]	102/101	60/68	0.93 (0.81,1.07)	0%	0.34
	ICU mortality	[9, 10, 14]	84/63	53/44	0.91 (0.72,1.14)	0%	0.41
	Hospital mortality	[13]	10/10	5/4	1.25 (0.4,3.33)		0.66
	90-day mortality	[2]	13/17	12/16	0.98 (0.81,1.19)		0.85
	More severe septic shock	[2, 9, 10, 13, 14]	107/90	70/64	0.96 (0.82,1.11)	0%	0.55
	Less severe septic shock	[8, 20,21,22,23]	364/367	157/166	0.72 (0.40,1.29)	43%	0.14
	Exclusion of the largest trial	[2, 9, 10, 13, 14, 20,21,22,23]	211/191	123/129	0.91 (0.81,1.03)	0%	0.14
	Exclusion of pediatric patients	[2, 8,9,10, 13, 20,21,22,23]	441/429	207/210	0.95 (0.85,1.05)	0%	0.31

Ctrl control group, DA dopamine, ICU intensive care unit, NE norepinephrine, RR risk ratio, TP terlipressin group

ISSN: 2052-0492